174 results on '"Courbon, Frédéric"'
Search Results
2. Impact of different models based on blood samples and images for bone marrow dosimetry after 177Lu-labeled somatostatin-receptor therapy
3. Insertion of synthetic lesions on patient data: a method for evaluating clinical performance differences between PET systems
4. Dosimetry for targeted radionuclide therapy in routine clinical practice: experts advice vs. clinical evidence
5. An extended bore length solid-state digital-BGO PET/CT system: design, preliminary experience, and performance characteristics
6. Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402): a multicentre, randomised, controlled phase 2 trial
7. Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project
8. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study
9. Efficacy and safety of 177Lu‑DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study
10. Evaluation of a method based on synthetic data inserted into raw data prior to reconstruction for the assessment of PET scanners
11. Impact of different models based on blood samples and images for bone marrow dosimetry after 177Lu-labeled somatostatin-receptor therapy.
12. Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)
13. Dosimetry for targeted radionuclide therapy in routine clinical practice: experts advice vs. clinical evidence
14. An extended bore length solid-state digital-BGO PET/CT system: design, preliminary experience, and performance characteristics
15. Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice
16. Receptor radionuclide targeting for neuroendocrine tumors (NET) diagnostic and therapy
17. Chemoradiotherapy for locally advanced cervix cancer without aortic lymph node involvement: can we consider metabolic parameters of pretherapeutic FDG-PET/CT for treatment tailoring?
18. Evaluation of the Interaction of Amino Acid Infusion on 177Lu-Dotatate Pharmacokinetics in Patients with Gastroenteropancreatic Neuroendocrine Tumors
19. RadioLigand Therapy with [177Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France
20. Diagnosis of an intestinal mucormycosis ‘fungus ball’ located with PET/CT with [18F] FDG-PET/CT
21. Supplementary Data from Preclinical and Clinical Evidence that Deoxy-2-[18F]fluoro-D-glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer
22. A clinical evaluation of the impact of the Bayesian penalized likelihood reconstruction algorithm on PET FDG metrics
23. RadioLigand Therapy with [ 177 Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France.
24. Additional file 1 of Evaluation of a method based on synthetic data inserted into raw data prior to reconstruction for the assessment of PET scanners
25. Nonsurgical giant cell tumour of the tendon sheath or of the diffuse type: Are MRI or 18F-FDG PET/CT able to provide an accurate prediction of long-term outcome?
26. Comparison of Two Types of Amino Acid Solutions on 177Lu-Dotatate Pharmacokinetics and Pharmacodynamics in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors
27. Coregistration of Prechemotherapy PET-CT for Planning Pediatric Hodgkin's Disease Radiotherapy Significantly Diminishes Interobserver Variability of Clinical Target Volume Definition
28. Evaluation of a Method Combining Physical Experiment and Data Insertion For the Assessment of PET-CT Systems
29. Development of a new radioligand for cholecystokinin receptor subtype 2 scintigraphy: From molecular modeling to in vivo evaluation
30. Efficacy and safety of 177Lu‑DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study.
31. Efficacy and safety of 177Lu-DOTATATE in patients (pts) with advanced pancreatic neuroendocrine tumors (pNETs): Data from the NETTER-R international, retrospective registry.
32. Functional testicular evaluation using PET/CT with 18F-fluorodeoxyglucose
33. Setting up a quantitative SPECT imaging network for a European multi-centre dosimetry study of radioiodine treatment for thyroid cancer as part of the MEDIRAD project
34. Evaluation of a Trainer Phantom in the Learning Phase of Sentinel Lymph Node Identification in Breast Cancer
35. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with Lu-177-Dotatate : an analysis of the NETTER-1 study
36. Breast Imaging: Understanding How Accuracy is Measured When Lesion are the Unit of Analysis
37. 18F-FDG PET/CT Identifies Predictors of Survival in Patients with Locally Advanced Cervical Carcinoma and Paraaortic Lymph Node Involvement to Allow Intensification of Treatment
38. Evaluation of 2 diuretic 18fluorine-fluorodeoxyglucose positron emission tomography/computed tomography imaging protocols for intrapelvic cancer
39. Comparison of Two Types of Amino Acid Solutions on 177Lu-DotatatePharmacokinetics and Pharmacodynamics in Patients with Metastatic GastroenteropancreaticNeuroendocrine Tumors
40. Gated 18F-FDG PET/CT of the Lung Using a Respiratory Spirometric Gating Device: A Feasibility Study
41. FDG-PET/CT identifies predictors of survival in patients with locally advanced cervical carcinoma and para-aortic lymph node involvement to increase treatment.
42. Clinical outcomes 1 year after empiric 131I therapy for hyperthyroid disorders
43. A pharmacokinetic interpretation of increasing concentrations of DEHP in haemodialysed patients
44. Étude capacite théranostique 2023-2024 - modélisation sur la base de la RIV-PSMA. Radiothérapie interne vectorisée (RIV),une approche théranostique a laquelle le patient doit avoir accès. Partie I : Consolidation nationale
45. Lanreotide depot/autogel before, during, and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumors (NETs): Data from the PRELUDE study.
46. Evaluation of the Interaction of Amino Acid Infusion on 177Lu-Dotatate Pharmacokinetics in Patients with Gastroenteropancreatic Neuroendocrine Tumors
47. Gated 18F-FDG PET/CT of the Lung Using a Respiratory Spirometric Gating Device: A Feasibility Study.
48. Evaluation of the Interaction of Amino Acid Infusion on 177Lu-Dotatate Pharmacokinetics in Patients with Gastroenteropancreatic Neuroendocrine Tumors.
49. 18F-fluorocholine PET/CT in patients with occult biochemical recurrence of prostate cancer: Detection rate, impact on management and adequacy of impact. A prospective multicentre study.
50. Nonsurgical giant cell tumour of the tendon sheath or of the diffuse type: Are MRI or 18F-FDG PET/CT able to provide an accurate prediction of long-term outcome?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.